Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
What COVID-19 Vaccines Can and Cannot Do: Setting Realistic Goals in the Current Pandemic
The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication.
Life-course immunization: Country landscape report
This project was commissioned to collect evidence focused on specific life-course approach to immunization (LCI) policies and priority geographies, and to compare available data sets and case studies before and during the COVID-19 pandemic.
News
Policy & Recommendations
Council calls for combatting vaccine hesitancy and closer EU cooperation
EU Ministers of Health approved Council conclusions on vaccination as one of the most effective tools for preventing disease and improving public health.
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains.
Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly
Seasonal influenza outbreaks, especially in high-risk groups such as the elderly, represent an important public health problem. Prevailing inadequate efficacy of seasonal vaccines is a crucial bottleneck.
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus antigens could form the basis for a universal influenza virus vaccine that has the potential to elicit long-lasting, broadly cross-reactive immune responses.
Addressing COVID-19 vaccine hesitancy
This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.
Older adults and COVID-19 vaccines
What do we know so far about older adults and COVID-19 vaccines? How long does the effect of the vaccine last and how successful have countries been in vaccinating older adults? WHO’s Dr Katherine O’Brien explains in Science in 5
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.
Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.